By

Luke Timmerman

25
Jul
2018

Finding the ‘Middle Market’ of Biotech VC: Chris Garabedian on The Long Run Podcast

Today’s guest on The Long Run podcast is Chris Garabedian. Garabedian is best known for his controversial stint as CEO of Cambridge, Mass.-based Sarepta Therapeutics, the developer of treatments for Duchenne Muscular Dystrophy. Whatever you may think of his tenure there — and the FDA’s decision to approve eteplirsen on a slim reed of clinical trial evidence – there is...
Read More